Tina Self serves as the global lead for the Biologics Manufacturing Capability Cluster, responsible for clinical through commercial manufacturing of Bayer’s biologics portfolio. She also serves as the Site Head for Bayer’s biotech campus in Berkeley, California. Prior to taking on this role in June 2024, she has advanced through positions of increasing responsibility in Quality, Biologics Manufacturing and Site Management. She is the proud leader of a fantastic team focused on manufacturing products that serve the global hemophilia community as well as producing the next generation of life-changing medicines. Tina has more than 25 years of experience with diverse product platforms including small molecule, autologous drug therapy, enzyme replacement, MABs and recombinant proteins in and has held leadership roles at Sanofi Genzyme and EMD Serono. Tina holds bachelor’s and master’s degrees from Georgia Southwestern State University and Johns Hopkins University and an MBA from Florida Atlantic University.

Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. We design our products and services to serve the most essential human needs of health and nutrition. At the same time, we strive to address some of the world’s biggest challenges presented by a growing and aging global population. At Bayer, we’re committed to driving sustainable development and generate a positive impact with our businesses. Through the power of science, we’re pioneering new possibilities that advance life for all of us. That means reimagining how we care for ourselves and one another by empowering everyday health, improving approaches to patient care, and finding better ways to nourish our communities around the world.